153 related articles for article (PubMed ID: 11149484)
1. Raloxifene reverses bone loss in postmenopausal women with mild asymptomatic primary hyperparathyroidism.
Zanchetta JR; Bogado CE
J Bone Miner Res; 2001 Jan; 16(1):189-90. PubMed ID: 11149484
[No Abstract] [Full Text] [Related]
2. The effect of raloxifene on markers of bone turnover in older women living in long-term care facilities.
Hansdóttir H; Franzson L; Prestwood K; Sigurdsson G
J Am Geriatr Soc; 2004 May; 52(5):779-83. PubMed ID: 15086661
[TBL] [Abstract][Full Text] [Related]
3. Raloxifene improves bone mass in osteopenic women with primary biliary cirrhosis: results of a pilot study.
Levy C; Harnois DM; Angulo P; Jorgensen R; Lindor KD
Liver Int; 2005 Feb; 25(1):117-21. PubMed ID: 15698408
[TBL] [Abstract][Full Text] [Related]
4. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z
Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
[TBL] [Abstract][Full Text] [Related]
5. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy.
Sarkar S; Mitlak BH; Wong M; Stock JL; Black DM; Harper KD
J Bone Miner Res; 2002 Jan; 17(1):1-10. PubMed ID: 11771654
[TBL] [Abstract][Full Text] [Related]
6. Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene.
McClung MR; Siris E; Cummings S; Bolognese M; Ettinger M; Moffett A; Emkey R; Day W; Somayaji V; Lee A
Menopause; 2006; 13(3):377-86. PubMed ID: 16735934
[TBL] [Abstract][Full Text] [Related]
7. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA
Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
[TBL] [Abstract][Full Text] [Related]
8. [Osteoporosis therapy compared. More solid bones with bisphosphonates].
MMW Fortschr Med; 2003 Aug; 145(31-32):55. PubMed ID: 14524081
[No Abstract] [Full Text] [Related]
9. [SERM and quality of bone].
Sohen S
Clin Calcium; 2004 Oct; 14(10):96-9. PubMed ID: 15577138
[TBL] [Abstract][Full Text] [Related]
10. [Defining the role of raloxifene as a therapeutic agent for postmenopausal osteoporosis: focus on its pharmacological properties].
Ohta H
Clin Calcium; 2004 Oct; 14(10):73-80. PubMed ID: 15577135
[TBL] [Abstract][Full Text] [Related]
11. [Evidence of raloxifene on postmenopausal osteoporosis].
Okano H
Nihon Rinsho; 2007 Nov; 65 Suppl 9():374-80. PubMed ID: 18161135
[No Abstract] [Full Text] [Related]
12. [Effects of SERMs on bone health. The effects of raloxifene on bone quality evaluated by hip structure analysis].
Takada J; Iba K; Yamashita T; Yoshizaki T
Clin Calcium; 2010 Mar; 20(3):355-63. PubMed ID: 20190365
[TBL] [Abstract][Full Text] [Related]
13. Who will benefit from treatment with selective estrogen receptor modulators (SERMs)?
Sambrook P
Best Pract Res Clin Rheumatol; 2005 Dec; 19(6):975-81. PubMed ID: 16301191
[TBL] [Abstract][Full Text] [Related]
14. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism.
Rossini M; Gatti D; Isaia G; Sartori L; Braga V; Adami S
J Bone Miner Res; 2001 Jan; 16(1):113-9. PubMed ID: 11149474
[TBL] [Abstract][Full Text] [Related]
15. The role of estrogens and related compounds in the management of primary hyperparathyroidism.
Marcus R
J Bone Miner Res; 2002 Nov; 17 Suppl 2():N146-9. PubMed ID: 12412792
[No Abstract] [Full Text] [Related]
16. Association of bone metabolism related genes polymorphisms with the effect of raloxifene hydrochloride on bone mineral density and bone turnover markers in postmenopausal women with osteoporosis.
Zhang ZL; He JW; Qin YJ; Huang QR; Liu YJ; Hu YQ; Li M
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Apr; 23(2):129-33. PubMed ID: 16604479
[TBL] [Abstract][Full Text] [Related]
17. [Raloxifene hydrochloride].
Itabashi A
Nihon Rinsho; 2004 Feb; 62 Suppl 2():528-35. PubMed ID: 15035185
[No Abstract] [Full Text] [Related]
18. Raloxifene therapy in the reduction of fractures.
Cefalu CA
Am Fam Physician; 2000 Mar; 61(5):1272, 1275, 1279-80. PubMed ID: 10735336
[No Abstract] [Full Text] [Related]
19. [Effect of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis].
Liu JL; Zhu HM; Huang QR; Zhang ZL; Li HL; Qin YJ; Zhang Y; Wei DL; Lu JH; Liu H; Chen XP; Liu YJ; Ekangaki A; Zheng YM; Diez-Perez A; Harpe K
Zhonghua Yi Xue Za Zhi; 2004 Feb; 84(4):269-73. PubMed ID: 15059505
[TBL] [Abstract][Full Text] [Related]
20. Raloxifene and vitamin K2 combine to improve the femoral neck strength of ovariectomized rats.
Iwamoto J; Yeh JK; Schmidt A; Rowley E; Stanfield L; Takeda T; Sato M
Calcif Tissue Int; 2005 Aug; 77(2):119-26. PubMed ID: 16059775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
